Dr. Geert Vanden Bossche
Creative thinker, innovator, entrepreneur and problem solver always open to new consultancy or career opportunities in the field of Vaccines, Life Sciences and/ or Global Health to deliver solutions to unmet medical needs.
Linked-In Bio: click for my full CV
Dr. Geert Vanden Bossche, PhD, DVM
My work and supportive advice are driven by a relentless passion to help bridge the gap between research and enterprise and to translate scientific breakthrough findings into competitive vaccine products. I strongly believe that a well-balanced synergy between multiple scientific disciplines combined with sound strategic insights and dedicated managerial support is critical to solving complex challenges in Human and Animal Health.
Profile: Experienced management professional; expert in vaccine R&D and early vaccine dvpt,; proficiency in program and grant management; used to working in a heavily interconnected environment (in private and nonprofit sector) while managing the needs of numerous stakeholders. Proven track record of success in designing and developing vaccines, managing dynamic, high-performing consortia, developing efficient processes to deliver impact, offering expert scientific-technical advice on complex immunisation projects, leading vaccine R&D work as CSO. Proficiency in program management, team leadership, patent writing, laboratory research, immunology, epidemiology, microbiology, vaccine technologies, preclinical vaccine dvpt. Substantial experience in strategic budgeting, CMC- and IP-related matters, incl. patent infringement and litigations. Over 2 decades of professional experience working in Europe and the US in managing implementation of immune interventions to address unmet medical needs. Highly familiar with major challenges in Global Health (as previously engaged with B. & M. Gates Foundation and GAVI).
I am particularly interested in engaging with international companies or organisations in the private or public sector or which are involved in public-private partnerships targeted at translational medicine programs, preferably in the field of Vaccine Innovation or Intellectual Property (e.g., IP issues, litigations related to infringement of vaccine patents).